Roche said the European Commission has approved its oral chemotherapy Xeloda (capecitabine) for the treatment of metastatic colorectal cancer in combination with any chemotherapy in all lines of treatment with or without Avastin. The new approval means that more patients suffering from colorectal cancer that has spread will now be able to take advantage of effective and innovative treatments with proven patient benefits.
Approval was based on the pivotal studies demonstrating Xeloda tablets providing patients with a more flexible treatment option with less hospital treatment time, whilst continuing to deliver the same survival benefits and safety as the previous standard chemotherapy intravenous (iv) 5-FU. The study also proved that Avastin in combination with chemotherapy allows patients to live significantly longer without their cancer progressing.
No comments:
Post a Comment